Erba Mannheim Group
About the Founder
Mission and Quality
Research & Development
Awards and Recognitions
ISO 13485 Certificate
ISO 9001 Certificate
Media & Events
Life at Transasia
Media & Events
Our participation in various global symposiums and events, gives us an opportunity to showcase to the world the entire gammut of products we offer. At Transasia Bio-Medicals Ltd., we encourage regular interactions with our business associates and partners, through seminars and conferences.
Some introduction text for Bichemistry products, industries it can be used, company’s vision regarding this product and future plans. Ideally we should have some content here for this
Select Your Country
India - Transasia Bio-Medicals Ltd.
USA - Erba Diagnostics, Inc.
USA - Diamedix Corporation
USA - ImmunoVision, Inc.
USA - JAS Diagnostics Inc.
USA - Drew Scientific
Italy - Delta Biologicals, s.r.l.
Czech Republic - Erba Lachema s.r.o
Russia - Erba Rus
France – Erba Diagnostics France SARL
Turkey - Erba DDS
You are here |
Media & Events
7 MAY 2008
India's In-Vitro Diagnostics Market Double Digit Annual Growth Drove Stronger Adoption of Automation With Over 1,800 Automated Systems Detected in 2007
Clearstate's IVD Gateway Database in India provides insights on instrument installation and test consumption trends by tracking market changes and usage patterns quarterly.
Singapore (PRWEB) May 7, 2008 -- Following the successful launch of its South East Asia (SEA) usage database for In-vitro Diagnostics (IVD) in 2006, Clearstate has expanded its IVD Gateway Database coverage to one of the largest and most challenging market in the region, India.
India's large geography and non-homogeneous usage environment demand a large sampling of hospital and stand-alone laboratories to ensure a robust and well-represented analysis of the IVD market. The Gateway database screened over 5,000 labs and surveyed in detail over 800 of the highest test volume facilities in India. Clearstate also took an additional measure to increase the thoroughness of the survey input and sizing estimates through validation with major distributors and suppliers.
Similar to the SEA database, the India database details unit installation of diagnostics analyzers, the volume consumption of reagents and tests assays, and the penetration of key IVD brands by city, model and user segment.
However, according to Ms. Ivy Teh, Clearstate's Managing Director, "We have further improved our database offering by providing value-added interpretations of market insights and share analysis. Instead of just presenting data, we now provide analysis on test breakdown run on automated vs. semi-automated systems, we have average installation age of over 10 leading brands and models and where they are located to help clients determine where and when replacements are coming up."
Ms. Teh added that the improved database showed more technology adoptions and higher end automated equipment purchases in large lab facilities especially in the South and West regions of India. For instance, automated systems in Clinical Chemistry have grown to close to 1,800 units across India, that represents only 12 - 15% of total analyzers installed but nearly 50% of the total revenue, valued at approximately USD 35 - 40 million in 2007. Trends observed in the database also revealed that local players are gaining stronger market presence, with Transasia extending its market leadership over international players specifically in Clinical Chemistry and Hematology.
Other interesting insights extracted from India's IVD Gateway include:
- Determine brand share and placements: Transasia's Erba Chem Series and Bayer's small RA Systems are the most placed Clinical Chemistry (CC) analyzers in all types of facilities. These analyzers act as back-up instruments in larger lab facilities. Bayer is pushing more of it Advia Systems that has seen a jump in installations in recent years while phasing out the old RA systems.
- Assess opportunity by geography: South and West India have the highest demand for IVD tests relative to other regions in the country, representing over 60% of total IVD tests. The majority of tests are still centered around key urban cities, primarily Mumbai, Delhi, Chennai, Bangalore and Kolkata.
© Erba Diagnostics
Web / 12 – 2006 / V1 / Dom
Developer : EVTL